Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2022.0143
Abstract: Key Points Question Does hyperthermic intraperitoneal chemotherapy (HIPEC) after primary or interval cytoreductive surgery increase survival in patients with ovarian cancer? Findings In this randomized clinical trial of 184 women with ovarian cancer, among those… read more here.
Keywords: surgery; survival; interval cytoreductive; ovarian cancer ... See more keywords
Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Surgical Oncology"
DOI: 10.1186/s12957-022-02517-1
Abstract: Background Cytoreductive surgery followed by systemic chemotherapy is the standard of treatment in advanced ovarian cancer where feasible. Neoadjuvant chemotherapy (NACT) followed by surgery is applicable where upfront cytoreductive surgery is not feasible because of… read more here.
Keywords: surgery; interval cytoreductive; cytoreductive surgery; prehabilitation ... See more keywords